University of Pennsylvania
2,198
259
420
1,422
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
9.7%
214 terminated/withdrawn out of 2198 trials
86.9%
+0.4% vs industry average
9%
206 trials in Phase 3/4
44%
620 of 1422 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (2198)
A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program
Role: collaborator
18F-FTHA IMAGING OF THE INTESTINAL AND CENTRAL LYMPHATIC SYSTEM
Role: lead
A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck
Role: collaborator
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
Role: lead
Early General Anesthesia to Limit Experiences of Trauma During Cesarean Section-Pilot Study
Role: lead
Patient Navigation to Improve Surgical Access in Primary Hyperparathyroidism
Role: lead
[18F]FES PET/CT in Endocrine Refractory Breast Cancer
Role: lead
Providing Oxygen During Intubation in the NICU Trial
Role: lead
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
Role: collaborator
Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)
Role: collaborator
CD45BE-HSPC + CART-45 Cells
Role: lead
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
Role: lead
Use of Transcutaneous Electrical Nerve Stimulation Device, Reletex Reliefband, With Current ERAS (Enhanced Recovery After Surgery) Protocol to Further Decrease Postoperative Nausea and Vomiting in the Bariatric Surgical Patient Within the First 24 Hours Postoperatively.
Role: lead
Bridges: A Digital Intervention to Increase Workplace Belonging
Role: collaborator
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
Role: lead
HIV-Mental Illness Stigma Reduction and Outcomes in Malawi
Role: lead
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
Role: lead
Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention
Role: lead
Colorectal Cancer Screening Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters
Role: lead
Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters
Role: lead